Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

You are here:  Home >>  News >>  Editors’ Picks >>  Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(1)

Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(1)

June 05, 2018 By Siyi

The market performance of the autoimmune drug market has been mounting and rapidly growing in recent years, with enormous potential and frequent blockbuster drugs. There were 3 autoimmune drugs among the top 4 in the annual global drug sales rankings, and even the strong oncology drug market had to “give in” in the face of the overwhelming momentum of the autoimmune drug market.

Company

Pharmaceutical product

Target

Field

2015 sales

2016 sales

2017 sales

Trend

AbbVie

Humira (adalimumab)

Anti-TNFα monoclonal antibody

Autoimmunity

140.12

160.78

184.27

14.60%

Amgen/Pfizer/Takeda

Enbrel (etanercept)

TNFα fusion protein

Autoimmunity

88.97

88.74

80.78

-9%

J & J/MSD/Mitsubishi Tanabe

Remicade (infliximab)

Anti-TNFα monoclonal antibody

Autoimmunity

83.55

82.34

77.28

-9.30%

J & J

Stelara (ustekinumab)

Anti-IL12/23 monoclonal antibody

Autoimmunity

24.74

32.32

40.11

24.1%

BMS/Ono Pharmaceutical

Orencia (abatacept)

CD 86 and CD80 inhibitor

Autoimmunity

19.58

23.92

26.08

9%

Novartis

Cosentyx (secukinumab)

Anti-IL-17A monoclonal antibody

Autoimmunity

2.61

11.28

20.71

84%

Roche

(CHF)

Actemra/RoActemra (tocilizumab)

Anti-IL-6 monoclonal antibody

Autoimmunity

14.32

16.97

19.26

14%

J & J/MSD

Simponi/Simponi Aria (golimumab)

Anti-TNFα monoclonal antibody

Autoimmunity

13.28

17.45

18.33

5.0%

UCB (EUR)

Cimzia (certolizumab)

Anti-TNFα monoclonal antibody

Autoimmunity

10.83

13.07

14.24

9.0%

Pfizer

Xeljanz (tofacitinib)

JAK inhibitor

Autoimmunity

5.23

9.27

13.45

45%

Celgene

Otezla (apremilast)

PDE4 inhibitor

Autoimmunity

4.72

10.17

12.79

25.8%

The 2017 sales of the top 11 autoimmune drugs were USD 50.73 billion.

TNFα inhibitors have indications across a dozen of diseases associated with autoimmunity, and became the king variety on the autoimmune drug market as led by Humira. The total sales of the 5 anti-TNFα monoclonal antibodies reached USD 37.49 billion in 2017, accounting for 73.9% of the total. However, there have been marketed generic drugs of Enbrel and Remicade, and even a drug with strong sales like Humira could not stop the decline of the variety’s future market after years of domination.

With impacts from generic drugs after patent expiration of original drugs and the strong rise of non-anti-TNFα monoclonal antibodies, the internal and external troubles result in anti-TNFα monoclonal antibodies to be overwhelmed.

自身免疫药物近三年市场销售

Market Sales of Autoimmune Drugs in Recent Three Years

TNFα单抗销售额

Sales of anti-TNFα monoclonal antibodies

非TNFα单抗销售额

Sales of non-anti-TNFα monoclonal antibodies

The launch of anti-IL-6 monoclonal antibodies and JAK inhibitors that are indicated for rheumatoid arthritis and anti-IL-23/17A monoclonal antibodies that are indicated for psoriasis has slowly broken the status quo of anti-TNFα monoclonal antibodies’ domination, and those drugs are rapidly growing, with potential of becoming blockbuster drugs: their sales rose from USD 7.12 billion in 2015 to USD 13.24 billion in 2017, to account for 26.1%, and their proportion is expected to reach about 35% in 2022.

Keep reading: Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(2)

Register as Visitor to CPhI China 2018!

Readers'Comments
Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
网页对话
live chat